下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Trust Co. of Vermont Buys Shares of 116 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
佛蒙特州信托公司购买116Vertex制药公司股票(纳斯达克代码:VRTX)

Defense World ·  {{timeTz}}

Trust Co. of Vermont bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 116 shares of the pharmaceutical company's stock, valued at approximately $33,000.

根据美国证券交易委员会的最新披露,佛蒙特州的信托公司在第二季度购买了Vertex制药公司(VRTX-GET Rating)的新股份。该公司购买了116股这家制药公司的股票,价值约3.3万美元。

A number of other hedge funds have also modified their holdings of the business. Procyon Advisors LLC increased its stake in shares of Vertex Pharmaceuticals by 2.8% during the 2nd quarter. Procyon Advisors LLC now owns 1,366 shares of the pharmaceutical company's stock worth $385,000 after purchasing an additional 37 shares in the last quarter. Nkcfo LLC increased its stake in shares of Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Nkcfo LLC now owns 8,515 shares of the pharmaceutical company's stock worth $2,399,000 after purchasing an additional 40 shares in the last quarter. J2 Capital Management Inc grew its stake in Vertex Pharmaceuticals by 2.2% in the 1st quarter. J2 Capital Management Inc now owns 1,915 shares of the pharmaceutical company's stock worth $500,000 after acquiring an additional 41 shares during the period. CHURCHILL MANAGEMENT Corp grew its stake in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. CHURCHILL MANAGEMENT Corp now owns 7,935 shares of the pharmaceutical company's stock worth $2,236,000 after acquiring an additional 42 shares during the period. Finally, Evoke Wealth LLC grew its stake in Vertex Pharmaceuticals by 32.8% in the 1st quarter. Evoke Wealth LLC now owns 174 shares of the pharmaceutical company's stock worth $45,000 after acquiring an additional 43 shares during the period. 91.33% of the stock is owned by hedge funds and other institutional investors.

其他一些对冲基金也调整了对该公司的持股比例。Procyon Advisors LLC在第二季度将其在Vertex制药公司的股份增加了2.8%。Procyon Advisors LLC现在拥有这家制药公司1,366股股票,价值385,000美元,上个季度又购买了37股。Nkcfo LLC在第二季度将其在Vertex PharmPharmticals的股份增加了0.5%。Nkcfo LLC现在拥有这家制药公司8,515股股票,价值2,399,000美元,上个季度又购买了40股。第一季度,J2资本管理公司在Vertex PharmPharmticals的持股增加了2.2%。J2资本管理公司在此期间额外收购了41股,现在拥有1,915股这家制药公司的股票,价值50万美元。丘吉尔管理公司在第二季度增持了Vertex PharmPharmticals 0.5%的股份。丘吉尔管理公司(Churchill Management Corp)在此期间额外收购了42股,目前拥有7,935股辉瑞股票,价值2,236,000美元。最后,Evoke Wealth LLC在第一季度增持了Vertex PharmPharmticals 32.8%的股份。Evoke Wealth LLC在此期间额外收购了43股,现在拥有174股这家制药公司的股票,价值4.5万美元。91.33%的股票由对冲基金和其他机构投资者持有。

Get
到达
Vertex Pharmaceuticals
Vertex制药公司
alerts:
警报:

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Several analysts have commented on the stock. Argus lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a "buy" rating in a research note on Monday, June 13th. Cantor Fitzgerald assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, July 12th. They issued an "overweight" rating and a $365.00 target price for the company. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $291.00 to $307.00 and gave the stock an "overweight" rating in a research note on Friday, August 5th. HC Wainwright lifted their target price on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Friday, August 5th. Finally, Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $250.00 to $253.00 and gave the company an "equal weight" rating in a report on Monday, August 8th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $291.65.

几位分析师对该股发表了评论。6月13日,周一,Argus在一份研究报告中将Vertex PharmPharmticals的目标价从275.00美元上调至280.00美元,并给予该股“买入”评级。坎托·菲茨杰拉德在7月12日星期二的一份研究报告中对Vertex制药公司的股票进行了报道。他们对该公司的评级为“增持”,目标价为365.00美元。巴克莱将Vertex PharmPharmticals股票的目标价从291.00美元上调至307.00美元,并在周五的一份研究报告中给予该股“增持”评级。8月5日,在一份研究报告中,HC Wainwright将Vertex PharmPharmticals股票的目标价从275.00美元上调至300.00美元,并给予该股“买入”评级。最终,摩根士丹利在8日周一的一份报告中将顶点制药的目标价从250.00美元上调至253.00美元,并给予该公司“同等权重”的评级。6名分析师对该股的评级为持有,11名分析师发布了买入评级,一名分析师对该公司给予了强烈的买入评级。根据MarketBeat,该股目前的平均评级为“中等买入”,平均目标价为291.65美元.

Insiders Place Their Bets

内部人士下注

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $305.06, for a total value of $3,565,846.34. Following the transaction, the chief executive officer now owns 99,598 shares in the company, valued at approximately $30,383,365.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through
在Vertex PharmPharmticals的其他消息中,首席执行官Reshma Kewalramani在8月15日星期一的一笔交易中出售了11,689股该公司的股票。这些股票的平均价格为305.06美元,总价值为3,565,846.34美元。交易完成后,这位首席执行官现在拥有该公司99,598股股票,价值约30,383,365.88美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过
. In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $305.06, for a total value of $3,565,846.34. Following the transaction, the chief executive officer now owns 99,598 shares in the company, valued at approximately $30,383,365.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through
。在Vertex PharmPharmticals的其他消息中,首席执行官Reshma Kewalramani在8月15日星期一的一笔交易中出售了11,689股该公司的股票。这些股票的平均价格为305.06美元,总价值为3,565,846.34美元。交易完成后,这位首席执行官现在拥有该公司99,598股股票,价值约30,383,365.88美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过
. Also, COO Stuart A. Arbuckle sold 22,173 shares of the business's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $303.93, for a total transaction of $6,739,039.89. Following the completion of the sale, the chief operating officer now directly owns 45,278 shares of the company's stock, valued at approximately $13,761,342.54. The disclosure for this sale can be found
。此外,首席运营官斯图尔特·A·阿巴克在一笔日期为8月15日星期一的交易中出售了22,173股该公司股票。该股以303.93美元的平均价格出售,总成交金额为6739,039.89美元。出售完成后,首席运营官现在直接拥有45,278股公司股票,价值约13,761,342.54美元。关于这次销售的披露可以找到
. Insiders have sold 196,831 shares of company stock worth $56,532,979 in the last quarter. 0.40% of the stock is owned by corporate insiders.
。上个季度,内部人士出售了196,831股公司股票,价值56,532,979美元。0.40%的股份由企业内部人士持有。

Vertex Pharmaceuticals Stock Performance

Vertex制药类股表现

NASDAQ:VRTX opened at $289.54 on Monday. The company has a current ratio of 4.50, a quick ratio of 4.36 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $74.26 billion, a price-to-earnings ratio of 23.41, a PEG ratio of 2.05 and a beta of 0.42. The firm's fifty day simple moving average is $287.25 and its 200 day simple moving average is $275.78. Vertex Pharmaceuticals Incorporated has a twelve month low of $176.36 and a twelve month high of $305.95.

纳斯达克:VRTX周一开盘报289.54美元。该公司的流动比率为4.50,速动比率为4.36,债务权益比率为0.04。该公司市值为742.6亿美元,市盈率为23.41倍,聚乙二醇率为2.05倍,贝塔系数为0.42。该公司的50日简单移动均线切入位为287.25美元,200日简单移动均线切入位为275.78美元。Vertex制药公司的股价为176.36美元的12个月低点和305.95美元的12个月高位。

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.25 EPS for the quarter, topping analysts' consensus estimates of $3.05 by $0.20. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The firm had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the business posted $2.80 EPS. The firm's revenue was up 22.5% compared to the same quarter last year. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 12.67 earnings per share for the current fiscal year.

顶点制药(纳斯达克:VRTX-GET评级)最近一次发布季度收益数据是在8月4日星期四。这家制药公司公布本季度每股收益为3.25美元,比分析师普遍预期的3.05美元高出0.20美元。Vertex PharmPharmticals的净利润率为38.26%,股本回报率为31.22%。该公司本季度营收为22.亿美元,而分析师预期为21.3亿美元。在去年同一季度,该业务公布的每股收益为2.80美元。与去年同期相比,该公司的收入增长了22.5%。作为一个整体,股票研究分析师预计,Vertex PharmPharmticals Inc.将公布本财年每股收益12.67美元。

Vertex Pharmaceuticals Profile

Vertex PharmPharmticals简介

(Get Rating)

(获取评级)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Vertex制药公司是一家生物技术公司,致力于开发治疗囊性纤维化的疗法并将其商业化。该公司销售SYMDEKO/SYMKEVI、Orkambi和Kalydeco,用于治疗囊性纤维化患者,这些患者的囊性纤维化跨膜传导调节基因具有特定突变;TRIKAFTA用于治疗至少有一种F508del突变的6岁或6岁以上的CF患者。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • 免费获取StockNews.com关于Vertex PharmPharmticals的研究报告(VRTX)
  • 阿彻·丹尼尔斯·米德兰:49年增长的红利英雄
  • 全自动拖拉机会让迪尔成为农业领域的特斯拉吗?
  • 麦格纳国际是您的汽车和电动汽车一站式库存
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat:回顾一周9/26-9/30

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接受Vertex制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vertex制药和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。